Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acre, Advisor, agitation, ago, Alcon, alter, Americo, Amgen, apixaban, Arca, AstraZeneca, ATRIPLA, Barr, biosimilar, blended, Brazilian, Bulgaria, calibration, Centre, CEO, clause, collusion, Congressional, contemplated, crime, CT, cytotoxic, dacarbazine, dapagliflozin, database, Deloitte, device, digit, disallowance, displayed, disrupt, distributorship, double, EFFERLAGAN, effervescent, eighteen, Eli, endpoint, enjoin, enjoined, enrollment, explanatory, fever, FTR, GLEEVEC, graph, Guidant, Guideline, Helmholtz, holder, Hybrid, hydrochlorothiazide, imatinib, immunoscience, implied, incapable, incompatible, Infektionsforschung, inflationary, input, Interbank, irrevocable, KENALOG, knowingly, Korean, land, learned, leaseback, legacy, Lilly, lock, lodged, LUMINITY, lymphoid, Majeure, Manati, Marchese, meslylate, mesylate, methotrexate, mg, Ministry, misled, misrepresented, Monte, multiemployer, myeloid, myloid, nonvested, NORVIR, NY, NYSE, Oakland, observed, obstruction, Ohio, onRating, operationally, output, overfunded, override, paracetamol, path, pathway, Pfizer, pivotal, placement, pledge, pledged, PMDA, point, pre, precipitously, premium, quantify, quantifying, radiation, rehearing, remeasurement, renminbi, renovate, repayment, resistance, Ritonavir, Romania, Rowan, RxUSA, Sampson, Sandoz, securitized, seller, Sherman, simulation, specialist, SPRYCEL, Starkman, Stephenson, steroid, Sun, Synthon, tabular, taxpayer, TechneLite, technique, thromboembolic, timeframe, Touche, Tribunal, TRICARE, TRIZIVIR, TRx, tyrosine, unlawful, unqualified, UNRESOLVED, untreated, unwind, upheld, variance, Weisz, welfare, wrongly, Zentrum
Removed:
accretion, ACE, actuarially, advisory, agonist, Alabama, Anthony, anticompetitive, Arizona, autoimmune, Bodnar, Botanical, Bush, BUSPAR, challenging, close, closed, coated, commerce, compendia, comprise, conflict, Connecticut, consolidate, continent, correct, corrected, declined, deficiency, deliver, deploy, dictated, disproportionate, disseminated, Dixon, downsize, downsizing, EITF, Energy, enteric, essentially, EXCEDRIN, false, falsely, FAS, FTC, grew, Heimbold, Hooper, House, Howson, immune, improperly, indemnify, inside, Intercontinental, involvement, ischemic, Jr, losing, master, McGoldrick, metabolic, metformin, Mississippi, Montana, Nevada, NS, older, overstating, phenylpropanolamine, pioneer, PPA, PPAR, pretrial, profile, promise, published, PwC, readily, recover, reorganization, reorganized, restitution, Ringrose, secondary, separation, setting, settled, sNDA, solution, STADOL, staffing, statin, stretch, subordinated, subpoena, subsidy, sufficiently, Tamar, Treasurer, treble, tubulin, varied, VIDEX, VIE, vitamin, Weizmann, Wendy, West, workdown
Filing tables
Filing exhibits
- 10-K Annual report
- 10 Bristol-myers Squibb Company 2002 Stock Incentive Plan
- 10 Form of Agreement
- 10 Form of Performance Shares Agreement
- 10 Form of Restricted Stock Units Agreement
- 12 Statement Re Computation of Ratios
- 21 Subsidiaries of the Registrant
- 23 Consent of Deloitte & Touche LLP
- 23 Consent of Pricewaterhousecoopers LLP
- 31 Section 302 Certification Letter
- 31 Section 302 Certification Letter
- 32 Section 906 Certification Letter
- 32 Section 906 Certification Letter
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 12.
Computation of Earnings to Fixed Charges
5-Year Ratio of Earnings to Fixed Charges: | 2006 | 2005 | 2004 | 2003 | 2002 | |||||||||||||||
Dollars in Millions | ||||||||||||||||||||
Earnings | ||||||||||||||||||||
Earnings from continuing operations before minority interest and income taxes | $ | 2,635 | $ | 4,516 | $ | 4,418 | $ | 4,680 | $ | 2,748 | ||||||||||
Less: | ||||||||||||||||||||
Equity in net income of affiliates | 474 | 334 | 273 | 151 | 80 | |||||||||||||||
Income adjusted for equity income | 2,161 | 4,182 | 4,145 | 4,529 | 2,668 | |||||||||||||||
Add: | ||||||||||||||||||||
Fixed charges | 566 | 408 | 369 | 361 | 420 | |||||||||||||||
Distributed income of equity investments | 439 | 383 | 278 | 155 | 125 | |||||||||||||||
Pre-tax losses of equity investees | 10 | 9 | 3 | 40 | 52 | |||||||||||||||
Less: | ||||||||||||||||||||
Capitalized interest | (18 | ) | (9 | ) | (10 | ) | (35 | ) | (16 | ) | ||||||||||
Total Earnings | $ | 3,158 | $ | 4,973 | $ | 4,785 | $ | 5,050 | $ | 3,249 | ||||||||||
Fixed Charges | ||||||||||||||||||||
Interest and debt expense | $ | 498 | $ | 349 | $ | 310 | $ | 277 | $ | 364 | ||||||||||
Capitalized interest | 18 | 9 | 10 | 35 | 16 | |||||||||||||||
One-third of rental expense | 50 | 50 | 49 | 49 | 40 | |||||||||||||||
Total Fixed Charges | $ | 566 | $ | 408 | $ | 369 | $ | 361 | $ | 420 | ||||||||||
Ratio of Earnings to Fixed Charges | 5.58 | 12.19 | 12.97 | 13.99 | 7.74 |
E-12-1